Skip to main content
Log in

Athletes, nonsteroidal anti-inflammatory drugs, coxibs, and the gastrointestinal tract

Current Sports Medicine Reports

Abstract

Nonsteroidal anti-inflammtory drugs (NSAIDs) are the most common self-administered and prescribed drugs taken in the United States. From 30% to 50% of those using these medications experience some degree of gastrointestinal (GI) side effect. Independent of NSAID use, a majority of athletes suffer GI symptoms, most of which has been documented in endurance athletes. Studies of NSAID use in patients with chronic osteo- and rheumatoid arthritis have defined a set of factors that can identify those who are at higher risk of serious GI events. Using such a model, clinicians can choose either to discontinue NSAID use, or prescribe a lower-risk NSAID or coxib (rofecoxib, celecoxib), prophylaxis with misoprostol, or proton pump inhibitor. Coxibs have been designed to decrease GI ulceration and bleeding by selective inhibition of cyclooxygenase-2, and offer an option for patients at high risk of GI hemorrhage. There are data suggesting that rofecoxib may be associated with an increased risk of myocardial infarction, and until further data are available, caution should be used when considering its prescription to patients at high risk of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Griffin MR: Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998, 104:23–29s.

    Article  Google Scholar 

  2. Talley NJ, Evans JM, Fleming KC, et al.: Nonsteroidal anti-inflammatory drugs and dyspespsia in the elderly. Dig Dis Sci 1995, 40:1345–1350.

    Article  CAS  PubMed  Google Scholar 

  3. Wolf MM, Lichenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–1899. Excellent review of risks, prophylaxis, and treatment.

    Article  Google Scholar 

  4. Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:2S-7S.

    Article  CAS  PubMed  Google Scholar 

  5. Lichenstein DR, Syngal S, Wolfe MM: Nonsteroidal antiinflammatory durgs and the gastrointestinal tract: the double edged sword. Arthritis Rheum 1995, 38:5–18.

    Article  Google Scholar 

  6. Jones R: Nonsteroidal anti-inflammatory drug prescribing: past, present and future. Am J Med 2001, 110A:4S-7S.

    Article  Google Scholar 

  7. Hawkey CJ, Lanas AI: Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med 2001, 110:79S-100S. Complete consensus from an expert panel on controversial issues.

    Article  CAS  PubMed  Google Scholar 

  8. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of acion for aspirin-like drugs. Nature 1971, 231:232–235.

    CAS  Google Scholar 

  9. Smith JH, Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971, 231:235–237.

    CAS  Google Scholar 

  10. Fitzgerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433–442. Scientific review of the evidence for coxibs.

    Article  CAS  PubMed  Google Scholar 

  11. Feldman M, McMahon T: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Int Med 2000, 132:134–143. An excellent and critical review of COX-2 studies.

    Article  CAS  PubMed  Google Scholar 

  12. Lipsky PE, Brooks P, Crofford LJ, et al.: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000, 160:913–920. Good review of COX 2 basic mechanisms and applicability.

    Article  CAS  PubMed  Google Scholar 

  13. Scheiman JM: NSAIDS, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996, 25:279–298.

    Article  CAS  PubMed  Google Scholar 

  14. Wallace JL: Mechanisms of protection and healing: current knowledge and future research. Am J Med 2001, 110:19S-23S. Reviews pathophysiology of cytoprotection and treatment.

    Article  CAS  PubMed  Google Scholar 

  15. Buttgereit F, Burmester GR, Simon LS: Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 specific inhibitors. Am J Med 2001, 110:13s-19s.

    Article  CAS  PubMed  Google Scholar 

  16. Jones J, Raud J: Nonsteroidal anti-inflammatory drug-associated dyspepsia: basic mechanisms and future research. Am J Med 2001, 110:14S-18S.

    Article  CAS  PubMed  Google Scholar 

  17. Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl 56):18–24.

    Google Scholar 

  18. Singh G: Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.

    Article  CAS  PubMed  Google Scholar 

  19. Hawkey CJ: Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: consensus and controversy. Am J Med 2001, 110:1S-3S.

    Article  CAS  PubMed  Google Scholar 

  20. Singh G, Ramey DR: NSAID induced gastrointestinal complications: the ARAMIS perspective. J Rheumatol 1998, 25(suppl 51):8–16. Data on the long term risks of NSAIDs in OA and RA patients.

    Google Scholar 

  21. Brun J, Jones R: Nonsteroidal anti-inflammatory drugassociated dyspepsia: the scale of the problem. Am J Med 2001, 110:12S-13S. Discusses cause and treatment of dyspepsia.

    Article  CAS  PubMed  Google Scholar 

  22. Silverstein FE, Faich G, Simon LS, et al.: Gastrointestinal toxicity with celcoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: a randomized controlled trial. JAMA 2000, 284:1247–1255. The definitive randomized clinical trial of celecoxib versus nonselective NSAIDs.

    Article  CAS  PubMed  Google Scholar 

  23. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520–1528. The definitive randomized clinical trial of rofecoxib versus naproxen.

    Article  CAS  PubMed  Google Scholar 

  24. Schmassmann A: Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:43S-51S.

    Article  CAS  PubMed  Google Scholar 

  25. Scheiman JM: NSAIDS, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996, 25:279–298.

    Article  CAS  PubMed  Google Scholar 

  26. Wright JP: Exercise and the gastrointestinal tract. South Afric Med J 1993, 83:50–52.

    CAS  Google Scholar 

  27. Moses FM: The effect of exercise on the gastrointestinal tract. Sports Med 1990, 3:159–172.

    Article  Google Scholar 

  28. Peters HP, De Vries WR, Vanberge-Henegouwen GP, Akkermans LM: Potential benefits and hazards of physical activity and exercise on the gastrointestinal tract. Gut 2001, 48:435–439. Good review of GI effects in athletes.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Strauss RH, Lanese RR, Leizman DJ: Illness and absence among wrestlers, swimmers, and gymnasts at a large university. Am J Sports Med 1988, 16:653–655.

    Article  CAS  PubMed  Google Scholar 

  30. Rudski SJ, Hazard H, Collinson D: Gastrointestinal blood loss in triathletes; its etiology and relationship to sports anemia. Aust J Sci Med Sport 1995, 1:3–8.

    Google Scholar 

  31. Mechrefe A, Wexler B, Feller E: Sports anemia and gastrointestinal bleeding in endurance athletes. Med Health Rhode Island 1997, 80:216–218.

    CAS  Google Scholar 

  32. Dang CV: Runner’s anemia. JAMA 2001, 286:714–716.

    Article  CAS  PubMed  Google Scholar 

  33. McMahon LFJr, Ryan MJ, Larson D, Fisher RL: Occult gastrointestinal blood loss in marathon runners. Ann Intern Med 1984, 100:846–847.

    Article  PubMed  Google Scholar 

  34. Robertson JD, Maughan RJ, Davidson RJ: Faecal blood loss in response to exercise. Br Med J Clin Res Ed 1987, 295:303–305.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Stewart JG, Ahlquist DA, McGill DB, et al.: Gastrointestinal blood loss and anemia in runners. Intern Med 1984, 100:843–845.

    CAS  Google Scholar 

  36. Choi SC, Choi SJ, Kim JA, Kim TH, et al.: The role of gastrointestinal endoscopy in long-distance runners with gastrointestinal symptoms. Eur J Gastroenterol Hepatol 2001, 13:1089–1094.

    Article  CAS  PubMed  Google Scholar 

  37. Nickerson HJ, Holubets MC, Weiler BR, et al.: Causes of iron deficiency in adolescent athletes.J Pediatr 1989, 114(4 Pt 1):657–663.

    Article  CAS  PubMed  Google Scholar 

  38. Smetanka RD, Lambert GP, Murray R, et al.: CV Intestinal permeability in runners in the 1996 Chicago marathon. Int J Sport Nutr 1999, 9:426–433.

    CAS  PubMed  Google Scholar 

  39. Fries JF, Williams CA, Block DA, Michael BA: Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991, 91:213–222.

    Article  CAS  PubMed  Google Scholar 

  40. Garcia Rodriguez LA: Variability in risk of gastrointestinal complications with different anti-inflammatory drugs. Am J Med 1998, 104:30S-34S.

    Article  CAS  PubMed  Google Scholar 

  41. Fries JF, Williams CA, Block DA: The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991, 34:1353–1360.

    Article  CAS  PubMed  Google Scholar 

  42. Schattenkirchner M: An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990, 10:56–65.

    CAS  PubMed  Google Scholar 

  43. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Int Med 1991, 115:787–796.

    Article  CAS  PubMed  Google Scholar 

  44. Henry D, Lim LL-Y, Garcia Rodgriguez LA, et al.: Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996, 312:1563–1566.

    Article  CAS  Google Scholar 

  45. Langman MJS, Weil J, Wainwright P, et al.: Risks of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet 1994, 343:1075–1078.

    Article  CAS  PubMed  Google Scholar 

  46. Hernandez-Diaz S, Garcia-Rodriquez LA: Epidemiologic Assessment of the safety of conventional nonsteroidal antiinflammatory drugs. Am J Med 2001, 110:20S-27S. Variable NSAID safety information.

    Article  CAS  PubMed  Google Scholar 

  47. Singh G, Terry R, Ramey DR, Fries JF, et al.: Comparative GI toxicity of NSAIDS [abstract 507]. Annual Meeting of the American College of Rheumatology, 1997.

  48. Singh, Ramey DR, Triadafilopoulus G, et al.: GI SCORE: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA [abstract 256]. Annual Meeting of the American College of Rheumatology, 1998. Gives details of the SCORE tool.

  49. Levy GD, Cheetham TC, Spence M: Nonsteroid electronic assessment of risk of gastrointestinal bleeding(NEAR) [abstract 431]. Annual Meeting American College of Rheumatology 2001.

  50. Shorr RI, Ray WA, Daugherty JR, Griffen MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153:1665–1670.

    Article  CAS  PubMed  Google Scholar 

  51. Almekinders LC: Anti-inflammatory treatment of muscular injuries in sport. An update of recent studies. Sports Med 1999, 6:383–388.

    Article  Google Scholar 

  52. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87–91.

    Article  CAS  PubMed  Google Scholar 

  53. Williams HJ, Ward HR, Egger JM, et al.: Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993, 36:1196–1206.

    Article  CAS  PubMed  Google Scholar 

  54. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ: Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000, 43:1905–1955.

    Article  Google Scholar 

  55. Jonsson BJ, Wahlqvist P: Management of nonsteroidal anti-inflammatory drug-associated lesions: a cost effectiveness perspective. Am J Med 1998, 104:81s-88s. Supports the use of acetaminophen and nonpharmacologic therapies.

    Article  CAS  PubMed  Google Scholar 

  56. Yeomans ND: Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug-associated ulcers. Am J Med 2001, 110A:24S-28S. Complete review of treatment and prophylaxis.

    Article  Google Scholar 

  57. Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435–1439.

    Article  CAS  PubMed  Google Scholar 

  58. Graham DY, White RH, Moreland W, et al., and the Misoprostol Study Group: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Int Med 1993, 119:257–262.

    Article  CAS  PubMed  Google Scholar 

  59. Silverstein FE, Graham DY, Senior JR, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995, 123:241–249. Results of the MUCOSA trial, proving misoprostol reduces GI bleeding.

    Article  CAS  PubMed  Google Scholar 

  60. Ekstrom P, Carling L, Wetterhus S, et al.: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996, 31:753–758.

    Article  CAS  PubMed  Google Scholar 

  61. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group[editorial]. N Engl J Med 1998, 338:727–734. Proves the efficacy of misoprostol.

    Article  CAS  PubMed  Google Scholar 

  62. Yeomans ND, Tulassay Z, Juhaz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719–726. Proves the efficacy of omeprazole.

    Article  CAS  PubMed  Google Scholar 

  63. Vane JR, Mitchell JA, Appleton I, et al.: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A 1994, 91:2046–2050.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Masferrer JL, Zweifel BS, Seibert K, Needelman P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990, 86:1375–1379.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Langman M, Jensen DM, Watson DJ, et al.: Adverse gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929–1933.

    Article  CAS  PubMed  Google Scholar 

  66. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282:1921–1928.

    Article  CAS  PubMed  Google Scholar 

  67. Okie S: Missing Data on Celebrex Full Study Altered Picture of Drug. Washington Post. August 5, 2001:A11.

  68. Levy G, Shoor SM: Report of the Third Annual Permanente Rheumatology Meeting. The Permanente Journal 2002, in press.

  69. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954–959. Meta-analysis of the cardiovascular risk of rofecoxib.

    Article  CAS  PubMed  Google Scholar 

  70. Catella-Lawson F, Croffored LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001, 110:28S-32S.

    Article  CAS  PubMed  Google Scholar 

  71. Lipani J: COX-2 inhibitors and cardiovascular risk. The data are inconclusive, and these drugs are needed. Cleve Clin J Med 2001, 68:957–964.

    Article  Google Scholar 

  72. Mandell BF: COX-2 inhibitors and cardiovascular risk. Point and counterpoint. Cleve Clin J Med 2001, 68:957–960.

    Article  CAS  PubMed  Google Scholar 

  73. Peloso PM, Scheiman JM: The economic implications of cyclo-oxygenase-2-specific inhibitors. Am J Med 2001, 110:50S-54S.

    Article  CAS  PubMed  Google Scholar 

  74. Graham DY: Helicobacter pylori and nonsteroidal antiinflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications—future research needs. Am J Med 2001, 110:58s-65s.

    Article  CAS  PubMed  Google Scholar 

  75. Lazzeroni M, Bianchi P: Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus. Am J Med 2001, 110:50s-54s.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shoor, S. Athletes, nonsteroidal anti-inflammatory drugs, coxibs, and the gastrointestinal tract. Curr Sports Med Rep 1, 107–115 (2002). https://doi.org/10.1007/s11932-002-0058-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11932-002-0058-y

Keywords

Navigation